NALDEMEDINE

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C32H34N4O6
Molecular Weight	570.6356
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of NALDEMEDINE

Structure Search

SMILES

CC(C)(NC(=O)C1=C(O)[C@@H]2OC3=C(O)C=CC4=C3[C@@]25CCN(CC6CC6)[C@H](C4)[C@]5(O)C1)C7=NC(=NO7)C8=CC=CC=C8

InChI

InChIKey=AXQACEQYCPKDMV-RZAWKFBISA-N

InChI=1S/C32H34N4O6/c1-30(2,29-33-27(35-42-29)18-6-4-3-5-7-18)34-28(39)20-15-32(40)22-14-19-10-11-21(37)25-23(19)31(32,26(41-25)24(20)38)12-13-36(22)16-17-8-9-17/h3-7,10-11,17,22,26,37-38,40H,8-9,12-16H2,1-2H3,(H,34,39)/t22-,26+,31+,32-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C32H34N4O6
Molecular Weight	570.6356
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 01:29:29 UTC 2023` Edited by `admin` on `Sat Dec 16 01:29:29 UTC 2023`
Record UNII	03KSI6WLXH
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NALDEMEDINE

Official Name

English

NALDEMEDINE [MI]

Common Name

English

NALDEMEDINE [USAN]

Common Name

English

17-(CYCLOPROPYLMETHYL)-6,7-DIDEHYDRO-4,5A-EPOXY-3,6,14-TRIHYDROXY-N-(2-(3-PHENYL-1,2,4-OXADIAZOL-5-YL)PROPAN-2-YL)MORPHINAN-7-CARBOXAMIDE

Common Name

English

Naldemedine [WHO-DD]

Common Name

English

naldemedine [INN]

Common Name

English

S-297995

Code

English

Classification Tree Code System Code

WHO-ATC

A06AH05

Created by admin on Sat Dec 16 01:29:29 UTC 2023 , Edited by admin on Sat Dec 16 01:29:29 UTC 2023

NDF-RT

N0000175691

Created by admin on Sat Dec 16 01:29:29 UTC 2023 , Edited by admin on Sat Dec 16 01:29:29 UTC 2023

Code System Code Type Description

INN

9484

Created by admin on Sat Dec 16 01:29:29 UTC 2023 , Edited by admin on Sat Dec 16 01:29:29 UTC 2023

PRIMARY

DAILYMED

03KSI6WLXH

Created by admin on Sat Dec 16 01:29:29 UTC 2023 , Edited by admin on Sat Dec 16 01:29:29 UTC 2023

PRIMARY

MERCK INDEX

m12021

Created by admin on Sat Dec 16 01:29:29 UTC 2023 , Edited by admin on Sat Dec 16 01:29:29 UTC 2023

PRIMARY

CAS

916072-89-4

Created by admin on Sat Dec 16 01:29:29 UTC 2023 , Edited by admin on Sat Dec 16 01:29:29 UTC 2023

PRIMARY

RXCUI

1876597

Created by admin on Sat Dec 16 01:29:29 UTC 2023 , Edited by admin on Sat Dec 16 01:29:29 UTC 2023

PRIMARY

EVMPD

SUB177220

Created by admin on Sat Dec 16 01:29:29 UTC 2023 , Edited by admin on Sat Dec 16 01:29:29 UTC 2023

PRIMARY

PUBCHEM

54732242

Created by admin on Sat Dec 16 01:29:29 UTC 2023 , Edited by admin on Sat Dec 16 01:29:29 UTC 2023

PRIMARY

SMS_ID

100000163094

Created by admin on Sat Dec 16 01:29:29 UTC 2023 , Edited by admin on Sat Dec 16 01:29:29 UTC 2023

PRIMARY

WIKIPEDIA

Naldemedine

Created by admin on Sat Dec 16 01:29:29 UTC 2023 , Edited by admin on Sat Dec 16 01:29:29 UTC 2023

PRIMARY

USAN

ZZ-09

Created by admin on Sat Dec 16 01:29:29 UTC 2023 , Edited by admin on Sat Dec 16 01:29:29 UTC 2023

PRIMARY

NCI_THESAURUS

C175156

Created by admin on Sat Dec 16 01:29:29 UTC 2023 , Edited by admin on Sat Dec 16 01:29:29 UTC 2023

PRIMARY

DRUG CENTRAL

5220

Created by admin on Sat Dec 16 01:29:29 UTC 2023 , Edited by admin on Sat Dec 16 01:29:29 UTC 2023

PRIMARY

ChEMBL

CHEMBL2105755

Created by admin on Sat Dec 16 01:29:29 UTC 2023 , Edited by admin on Sat Dec 16 01:29:29 UTC 2023

PRIMARY

DRUG BANK

DB11691

Created by admin on Sat Dec 16 01:29:29 UTC 2023 , Edited by admin on Sat Dec 16 01:29:29 UTC 2023

PRIMARY

FDA UNII

03KSI6WLXH

Created by admin on Sat Dec 16 01:29:29 UTC 2023 , Edited by admin on Sat Dec 16 01:29:29 UTC 2023

PRIMARY

EPA CompTox

DTXSID501030350

Created by admin on Sat Dec 16 01:29:29 UTC 2023 , Edited by admin on Sat Dec 16 01:29:29 UTC 2023

PRIMARY

Related Record Type Details


					V1N8F1RVVO

NALDEMEDINE TOSYLATE

SALT/SOLVATE -> PARENT


					2BJ58BX78W

KAPPA-TYPE OPIOID RECEPTOR

TARGET -> INHIBITOR

Comments:

Used recombinant human kappa-opioid receptor (expressed in HEK-293 cells), U-50488H as an agonist, and guanosine-5’-O-(3-(35S)thio) triphosphate ((35S)-GTP.GAMMA.S) as a ligand

Interaction Type:

ANTAGONIST

Qualification:

Kb

Amount:


					1PE72K8X46

MU-TYPE OPIOID RECEPTOR

TARGET -> INHIBITOR

Comments:

Used recombinant human mu-opioid receptor (expressed in CHO-K1 cells), DAMGO as an agonist, and guanosine-5’-O-(3-(35S)thio) triphosphate ((35S)-GTP.GAMMA.S) as a ligand

Interaction Type:

ANTAGONIST

Qualification:

Kb

Amount:


					2BJ58BX78W

KAPPA-TYPE OPIOID RECEPTOR

TARGET -> INHIBITOR

Comments:

RECOMBINANT HUMAN KAPPA-OPIOID RECEPTOR (EXPRESSED IN HEK-293 CELLS), (3H)-U69593 AS A LIGAND

Interaction Type:

BINDING

Qualification:

Ki

Amount:


					1PE72K8X46

MU-TYPE OPIOID RECEPTOR

TARGET -> INHIBITOR

Comments:

Kobs of (3H)-Naloxone was 0.233 (1/min).

Interaction Type:

BINDING

Qualification:

Association rate constant (Kobs)

Amount:


					22ES734693

MULTIDRUG RESISTANCE PROTEIN 1

TRANSPORTER -> SUBSTRATE

Amount:


					EV0PWK6TT6

DELTA-TYPE OPIOID RECEPTOR

TARGET -> INHIBITOR

Comments:

RECOMBINANT HUMAN DELTA-OPIOID RECEPTOR (EXPRESSED IN HEK-293 CELLS), (3H)-(D-ALA2, D-LEU5)-ENKEPHALIN (DADLE) AS A LIGAND

Interaction Type:

BINDING

Qualification:

Ki

Amount:


					1PE72K8X46

MU-TYPE OPIOID RECEPTOR

TARGET -> INHIBITOR

Comments:

T1/2 of (3H)-Naloxone was 0.266 min.

Interaction Type:

BINDING

Qualification:

T1/2 (the time until binding of the radiolabelled ligand to the receptor decreases to 50% after addition of an excess amount of unlabeled ligand)

Amount:


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Interaction Type:

BINDING

Amount:


					1PE72K8X46

MU-TYPE OPIOID RECEPTOR

TARGET -> INHIBITOR

Comments:

Based on slope of Schild regression, naldemedine monotosylate exhibited non-competitive antagonism to morphine, oxycodone, hydrocodone, and fentanyl-induced (35S)-GTP.gamma.S binding.

Interaction Type:

NON-COMPETITIVE INHIBITOR


					PUO0521HZV

CYTOCHROME P450 3A4

METABOLIC ENZYME -> SUBSTRATE

Amount:


					1PE72K8X46

MU-TYPE OPIOID RECEPTOR

TARGET -> INHIBITOR

Comments:

RECOMBINANT HUMAN MU-OPIOID RECEPTER (EXPRESSED IN CHO-K1 CELLS), (3H)-(D-ALA2, N-ME-PHE4, GLY5-OL)-ENKEPHALIN ACETATE SALT (DAMGO) AS A LIGAND

Interaction Type:

BINDING

Qualification:

Ki

Amount:


					EV0PWK6TT6

DELTA-TYPE OPIOID RECEPTOR

TARGET -> INHIBITOR

Comments:

Used recombinant human delta-opioid receptor (expressed in HEK-293 cells), (Met5)-enkephalin as an agonist, and guanosine-5’-O-(3-(35S)thio) triphosphate ((35S)-GTP.GAMMA.S) as a ligand

Interaction Type:

ANTAGONIST

Qualification:

Kb

Amount:


					1PE72K8X46

MU-TYPE OPIOID RECEPTOR

TARGET -> INHIBITOR

Comments:

Koff of (3H)-Naloxone was 0.266 (1/min).

Interaction Type:

BINDING

Qualification:

Dissociation rate constant (Koff)

Amount:

Related Record Type Details


					DUK8PZ84YX

NOR-NALDEMEDINE

METABOLITE LESS ACTIVE -> PARENT


					MQS88P23Q4

NALDEMEDINE-CARBOXYLIC ACID

METABOLITE LESS ACTIVE -> PARENT


					KUE3ZY3J1F

METABOLITE INACTIVE -> PARENT


					LK97CY7UA6

NALDEMEDINE 6-O-.BETA.-D-GLUCURONIDE

METABOLITE LESS ACTIVE -> PARENT


					7E7WC476CT

NALDEMEDINE-(7R)-7-HYDROXIDE

METABOLITE -> PARENT


					CSJ43DHV6P

NALDEMEDINE 3-O-.BETA.-D-GLUCURONIDE

METABOLITE INACTIVE -> PARENT

Related Record Type Details


					03KSI6WLXH

ACTIVE MOIETY

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Biological Half-life	PHARMACOKINETIC

Volume of Distribution	PHARMACOKINETIC